Bartosz Malkiewicz

2/ Updated EV-302 (2.5-yr f/u). EV+pembro as 1L SOC in la/mUC. PFS 12.5 vs 6.3 mo (HR 0.48); OS 33.8 vs 15.9 mo (HR 0.51) vs chemo. Durable benefit with no new safety signals. @tompowles1 @shilpaonc annalsofoncology.org/article/S0923-…

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU clinical trials in 2025! 1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%. @tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO nejm.org/doi/full/10.10…

MRI is a great tool in prostate cancer. The problem is, quality in practice might not be quality we see in studies. Nice study from @dr_coops showing that in the VA, MRI not good enough to rule out biopsy. jamanetwork.com/journals/jamao…

Remains one of the cheapest/easiest ways to minimize unnecessary testing, biopsy, diagnosis, or treatment: repeat a newly elevated PSA (without empiric abx) jamanetwork.com/journals/jamao…

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis jamanetwork.com/journals/jamao… Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy (ADT) combined with radiotherapy is highly dependent on both treatment duration and patient risk profile, with diminishing returns beyond roughly 9–12 months and increasing non–cancer-related mortality with prolonged therapy. Optimal duration varied by disease severity—shorter or no ADT for lower-risk intermediate disease, longer courses for higher-risk groups—highlighting that extended therapy is not universally beneficial. Because longer ADT improves cancer-specific outcomes but also increases other-cause mortality, the study emphasizes tailoring duration based on individual risk, comorbidities, life expectancy, and patient preference rather than applying uniform treatment lengths. #ProstateCancer @NicholasZaorsky @yilun_sun @StatMatt9 @DrHowardSandler @drjefstathiou @Soum_Roy_RadOnc @DrPaulNguyen @jeshoag @PBarataMD @angela_jia_ @MSteinbergMD @AmarUKishan @DrSpratticus @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

🧬 Cribriform architecture changes the story in localized prostate cancer. 🔥 ProtecT 15-year biopsy re-review shows who really needs treatment vs surveillance. 🎯 n = 712 with available slides (13 % cribriform+) 💊 Arms: ▫️ Active monitoring ▫️ Radical prostatectomy ▫️ Radiotherapy + neoadjuvant ADT 📊 Key Results • Cribriform + → ↑ metastasis risk (HR 3.61, 95 % CI 1.60-8.11) • RT + ADT → lowest metastasis (HR 0.35 vs active monitoring) • Surgery → HR 0.52 vs active monitoring (NS) • 15-yr metastasis (cribriform +): AM 25 % | Surg 26 % | RT + ADT 8 % • Cribriform –: 7 % | 4 % | 3 % ✅ Takeaway: Cribriform + = treat aggressively (RT + ADT best long-term control) Cribriform – = active surveillance still safe for most patients. 📖 Sushentsev et al. JAMA Oncology 2025. 🔗 doi.org/10.1001/jamaon… #OncoTwitter #MedTwitter #ProstateCancer #UroOnc @OncoAlert @myesmo @esmo_open @ASCO @JAMAOnc

Many thanks to my hosts @wojciechpiotrk1 @bartmalkiewicz Jan Łaszkiewicz and the rest of the wonderful Dept of Urology at Wroclaw Medical University observed really cutting edge Endourology and robotics. Also was interviewed by the local TV station as a highlight to my visit. @StanfordUrology

Our new SR and MA published in @EurUrolOncol evaluates focal therapy for localized PCa using prospective data only. Important for patient counselling. 📊 50 studies, 4,615 patients 📊 12-mo csPCa RFS in intermediate-risk: 79% (95% CI 74–83%) 🔗 doi.org/10.1016/j.euo.…

Histological subtypes/divergent differentiation (HS/DD) in UTUC = worse outcomes. In a review of 14,407 patients, HS/DD linked to higher stage/grade, more LNI/LVI, and worse CSS, OS, RFS. Detection should prompt aggressive tx + close follow-up. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Smarter staging in prostate cancer? 🙋🏼‍♂️🙋🏻‍♂️🙋🏾‍♂️In patients with intermediate/high-risk prostate cancer and negative PSMA PET (miN0), extended pelvic lymph node dissection (ePLND) remains a clinical dilemma. 🔍 This multi-institutional study (n = 282) externally validated five nomograms to predict lymph node invasion (LNI): ▪️ MSKCC ▪️ Briganti 2017 ▪️ Briganti 2019 ▪️ Amsterdam-Brisbane-Sydney ▪️ Briganti 2023 Key finding: ✅ The Briganti 2023 nomogram outperformed all others with highest accuracy (C-index: 77%) and spared 47% of unnecessary ePLNDs at a 5% cutoff—while missing only 3.8% of LNI cases! Clinical implications: 1.Negative PSMA PET ≠ no risk: ~13% still had LNI! 2.Micrometastases matter: PSMA PET may miss them due to spatial resolution limits. 3.Briganti 2023 helps tailor who really needs nodal dissection, balancing risks and benefits. pubmed.ncbi.nlm.nih.gov/39890547/ @GGandaglia @dr_rajwa @ArmandoStabile @Albert0Briganti @alexmottrie

Micro-ultrasonography-guided biopsy is noninferior to MRI-guided fusion biopsy for the detection of clinically significant prostate cancer in biopsy naïve men. ja.ma/4hzTwTo #EAU25 @JulianStruck @moisessocarras @ChrisFungMD @arvinkgeorge @TxetxuPereira

#eau25 What is your advice for a 65yo man with Parkinson and 80ml prostate? 💥Functional session: urodynamics first! 💥BPH surgery session: AEEP first! 💥CaP session: what is his PSA? 💥Patient session: LUTS is not so important to me

@lukasz_t_nowak @wojciechpiotrk1 @YAUEndourology @EndoPTU @PTUweb Congratulations Łukasz - you definitely deserve it👌

Honored to become an Associate Member of the YAU Endourology & Urolithiasis Group! Looking forward to exciting new scientific collaborations and advancing research in the field. I am deeply grateful for the invaluable scientific mentorship of @wojciechpiotrk1

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10.33…

Conventional imaging understages high-risk nonmetastatic prostate cancer. ☢️PSMA-PET was positive in 84% of cases, detecting M1 disease in 46%, polymetastatic in 24%. #ProstateCancer #PSMAPET #Oncology @OncoAlert @JAMANetworkOpen @APCCC_Lugano doi:10.1001/jamanetworkopen.2024.52971

Some statistics of the Journal 🌍 Numbers of articles accepted over the past 5 years

5-year (2020-2024) acceptance rate :

Editor's Choice: Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial by @nickva1 et al Read the full article here: buff.ly/3OSVsu6 Come back to read the Editorial! #UroSoMe #MedTwitter #eururol #EditorsChoice #ProstateCancer #PCa #Spotlight @GGiannarini

And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile. ⛹🏼‍♂️A new player for doublets in mHSPC! #ESMO24 Dr. Fred Saad @Silke_Gillessen @neerajaiims @umangtalking @DrRanaMcKay @JCO_ASCO doi.org/10.1200/JCO-24…

Insightful interpretation of the RADICALS-HD trial by @a_dalpra at yesterday’s PCa masterclass. Kudos to my friends @paolo_gontero, @oderdam, @GMarra_MD, and @peppinoiorio for organizing such a stellar event!